



**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**

USA: **RUO**

**Revised of 3 Feb. 2009 (Vers. 1.0)**

**NAME AND INTENDED USE**

ACPA is an indirect solid phase enzyme immunoassay (ELISA) for the quantitative measurement of IgG class autoantibodies against citrullinated Proteins (ACP) in human serum or plasma.

The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of rheumatoid arthritis.

**SUMMARY AND EXPLANATION OF THE TEST**

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. The main characteristic of RA is joint inflammation that results in joint damage and loss of function. An early diagnosis of RA and an immediate beginning of an appropriate treatment is important to prevent a complete joint damage. RA is diagnosed primarily on clinical manifestations and serological support has, up to now, been mainly restricted to the determination of autoantibodies against rheumatoid factor (RF). RF is a sensitive serological marker for RA with a moderate specificity of about 70%. In several studies it has been demonstrated that the determination of antibodies against citrullinated arginine residues in filament proteins occurs in RF negative patients. Citrullination is a peptidylarginine deiminase (PAD) catalysed process in which the amino acid arginine (Arg) is modified to citrulline. During this conversion, the positively charged NH<sub>2</sub>-group is hydrolyzed to an oxygen group.

The ACPA ELISA shows both a high specificity and a high sensitivity for autoantibodies against citrullinated proteins.

**PRINCIPLE OF THE TEST**

ACPA is bound to microwells. Antibodies against this antigen, if present in diluted serum or plasma, bind to the respective antigen. Washing of the microwells removes unspecific serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human IgG immunologically detects the bound patient antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue color. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow color is measured photometrically at 450 nm. The amount of colour is directly proportional to the concentration of IgG antibodies present in the original sample.

**WARNINGS AND PRECAUTIONS**

1. All reagents of this kit are strictly intended for in vitro diagnostic use only. In the United States, this kit is intended for Research Use Only.
2. Do not interchange kit components from different lots.
3. Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
4. Avoid contact with the TMB (3,3',5,5'-Tetramethyl-benzidine). If TMB comes into contact with skin, wash thoroughly with water and soap.

---

**DRG International Inc., USA**

**Fax: (908) 233-0758 • E-mail: [corp@drg-international.com](mailto:corp@drg-international.com) • Web: [www.drg-international.com](http://www.drg-international.com)**

**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**

USA: 

**Revised of 3 Feb. 2009 (Vers. 1.0)**

5. Avoid contact with the Stop Solution which is acid. If it comes into contact with skin, wash thoroughly with water and seek medical attention.
6. Some kit components (i.e. Controls, Sample buffer and Buffered Wash Solution) contain Sodium Azide as preservative. Sodium Azide (NaN<sub>3</sub>) is highly toxic and reactive in pure form. At the product concentrations (0.09%), though not hazardous. Despite the classification as nonhazardous, we strongly recommend using prudent laboratory practices (see 8., 9., 10).
7. Some kit components contain Proclin 300 as preservative. When disposing reagents containing Proclin 300, flush drains with copious amounts of water to dilute the components below active levels.
8. Wear disposable gloves while handling specimens or kit reagents and wash hands thoroughly afterwards.
9. Do not pipette by mouth.
10. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled.
11. Avoid contact between the buffered Peroxide Solution and easily oxidized materials; extreme temperature may initiate spontaneous combustion.

Observe the guidelines for performing quality control in medical laboratories by assaying controls and/or pooled sera. During handling of all kit reagents, controls and serum samples observe the existing legal regulations.

**CONTENTS OF THE KIT**

Package size	96 determ.
Qty.1	Divisible <b>microplate</b> consisting of 12 modules of 8 wells each, coated with citrullinated protein. Ready to use.
6 vials, 1.5 ml each	<b>Calibrators</b> with IgG class Anti-Citrullinated Protein antibodies (A-F) in a serum/buffer matrix (PBS, BSA, NaN <sub>3</sub> <0.1% (w/w)) containing: IgG: 0; 10; 20; 50; 150; and 500 U/ml. Ready to use.
2 vials, 1.5 ml each	<b>ACPA controls</b> in a serum/buffer matrix (PBS, BSA, NaN <sub>3</sub> <0.1% (w/w)) positive (1) and negative (2), for the respective concentrations see the enclosed package insert. Ready to use.
1 vial, 20 ml	<b>Sample buffer</b> (Tris, NaN <sub>3</sub> <0.1% (w/w)), yellow, concentrate (5x).
1 vial, 15 ml	<b>Enzyme conjugate</b> solution (PBS, Proclin 300 <0.5% (v/v)), (light red) containing polyclonal rabbit anti-human IgG; labelled with horseradish peroxidase. Ready to use.
1 vial, 15 ml	<b>TMB substrate solution.</b> Ready to use.
1 vial, 15 ml	<b>Stop solution</b> (acid). Ready to use.
1 vial, 20 ml	<b>Wash solution</b> (PBS, NaN <sub>3</sub> <0.1% (w/w)), concentrate (50x).

**STORAGE AND STABILITY**

1. Store the kit at 2-8 °C.
2. Keep microplate wells sealed in a dry bag with desiccants.

**Revised of 3 Feb. 2009 (Vers. 1.0)**

3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage and usage.
5. Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8 °C.

**MATERIALS REQUIRED****Equipment**

- Microplate reader capable of endpoint measurements at 450 nm
- Multi-Channel Dispenser or repeatable pipet for 100 µl
- Vortex mixer
- Pipets for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Data reduction software

**Preparation of reagents**

- Distilled or deionized water
- Graduated cylinder for 100 and 1000 ml
- Plastic container for storage of the wash solution

**SPECIMEN COLLECTION, STORAGE AND HANDLING**

1. Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
2. Allow blood to clot and separate the serum by centrifugation.
3. Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia is best avoided, but does not interfere with this assay.
4. Specimens may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.
5. Avoid repetitive freezing and thawing of serum samples. This may result in variable loss of autoantibody activity.
6. Testing of heat-inactivated sera is not recommended.



**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**



**Revised of 3 Feb. 2009 (Vers. 1.0)**

**PROCEDURAL NOTES**

1. Do not use kit components beyond their expiration dates.
2. Do not interchange kit components from different lots.
3. All materials must be at room temperature (20-28 °C).
4. Have all reagents and samples ready before start of the assay. Once started, the test must be performed without interruption to get the most reliable and consistent results.
5. Perform the assay steps only in the order indicated.
6. Always use fresh sample dilutions.
7. Pipette all reagents and samples into the bottom of the wells.
8. To avoid carryover contaminations change the tip between samples and different kit controls.
9. It is important to wash microwells thoroughly and remove the last droplets of wash buffer to achieve best results.
10. All incubation steps must be accurately timed.
11. Control sera or pools should routinely be assayed as unknowns to check performance of the reagents and the assay.
12. Do not re-use microplate wells.

For all controls, the respective concentrations are provided on the labels of each vial. Using these concentrations a calibration curve may be calculated to read off the patient results semiquantitatively.

**PREPARATION OF REAGENTS**

**Preparation of sample buffer**

Dilute the contents of each vial of the sample buffer concentrate (5x) with distilled or deionized water to a final volume of 100 ml prior to use.

Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

**Preparation of wash solution**

Dilute the contents of each vial of the buffered wash solution concentrate (50x) with distilled or deionized water to a final volume of 1000 ml prior to use.

Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

**Sample preparation**

Dilute all patient samples **1:100** with sample buffer before assay.

Therefore combine 10 µl of sample with 990 µl of sample buffer in a polystyrene tube. Mix well.

**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**

USA:

**Revised of 3 Feb. 2009 (Vers. 1.0)**

Controls are ready to use and need not be diluted.

**TEST PROCEDURE**

1. Prepare a sufficient number of microplate modules to accommodate controls and prediluted patient samples.
2. Pipet **100 µl** of calibrators, controls and prediluted patient samples in duplicate into the wells.

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	
<i>A</i>	SA	SE	P1	P5			SA-SF: standards A to F P1, P2...: patient sample 1, 2 ... C1: positive control C2: negative control
<i>B</i>	SA	SE	P1	P5			
<i>C</i>	SB	SF	P2	P..			
<i>D</i>	SB	SF	P2	P..			
<i>E</i>	SC	C1	P3				
<i>F</i>	SC	C1	P3				
<i>G</i>	SD	C2	P4				
<i>H</i>	SD	C2	P4				

3. Incubate for 30 minutes at room temperature (20-28 °C)
4. Discard the contents of the microwells and wash 3 times with **300 µl** of wash solution.
5. Dispense **100 µl** of enzyme conjugate into each well
6. Incubate for 15 minutes at room temperature
7. Discard the contents of the microwells and wash 3 times with 300 µl of wash solution
8. Dispense **100 µl** of TMB substrate solution into each well
9. Incubate for 15 minutes at room temperature
10. Add **100 µl** of stop solution to each well of the modules and incubate for 5 minutes at room temperature
11. Read the optical density at 450 nm and calculate the results. Bi-chromatic measurement with a reference at 600-690 nm is recommended.

**The developed color is stable for at least 30 minutes. Read optical densities during this time.**



**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**



**Revised of 3 Feb. 2009 (Vers. 1.0)**

**Automation**

The ACPA ELISA is suitable for use on open automated ELISA processors. The test procedure detailed above is appropriate for use with or without automation.

**INTERPRETATION OF RESULTS**

**1.1 Quality Control**

This test is only valid if the optical density at 450 nm for Positive Control (1) and Negative Control (2) as well as for the Calibrator A and F complies with the respective range indicated on the Quality Control Certificate enclosed to each test kit!

If any of these criteria is not fulfilled, the results are invalid and the test should be repeated.

**1.2 Calculation of results**

For the ACPA ELISA a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

**1.3 Recommended Lin-Log Plot**

First calculate the averaged optical densities for each calibrator well. Use lin-log graph paper and plot the averaged optical density of each calibrator versus the concentration. Draw the best fitting curve approximating the path of all calibrator points. The calibrator points may also be connected with straight line segments. The concentration of unknowns may then be estimated from the calibration curve by interpolation.

**1.4 Interpretation of results**

In a normal range study with serum samples from healthy blood donors the following ranges have been established with the ACPA assay.

	<u>ACPA IgG [U/ml]</u>
normal:	< 10
positive:	≥ 10

Positive results should be verified concerning the entire clinical status of the patient. Also every decision for therapy should be taken individually. It is recommended that each laboratory establishes its own normal and pathological ranges of Anti-Citrullinated Protein Antibodies in serum or plasma. The above reference ranges should be regarded as guidelines only.

Revised of 3 Feb. 2009 (Vers. 1.0)

**PERFORMANCE CHARACTERISTICS****1.5 Precision (Reproducibility)**

Statistics for coefficients of variation (CV) were calculated for each of three samples from the results of 24 determinations in a single run for Intra-Assay precision. Run-to-run precision was calculated from the results of 5 different runs with 6 determinations of each sample:

Sample No	Intra-Assay	
	Mean [U/ml]	CV [%]
1	35	3,8
2	394	5,4
3	937	4,9

Sample No	Inter-Assay	
	Mean [U/ml]	CV [%]
1	42	4,5
2	547	5,7
3	978	6,4

**1.6 Sensitivity**

The lower detection limit for ACPA was determined at 2 U/ml.

**1.7 Specificity**

The microplate is coated with citrullinated proteins. The ACPA test kits is specific only for autoantibodies against citrullinated proteins.

**1.8 Calibration**

Since no international reference preparation for ACPA antibodies is available, the system is calibrated in arbitrary units.

**LIMITATIONS OF PROCEDURE**

The ACPA ELISA is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated.

**INTERFERING SUBSTANCES**

No interference has been observed with haemolytic (up to 1000 mg/dL), lipemic (up to 3 g/dL triglycerides) or bilirubin (up to 40 mg/dL) containing sera.

Nor have any interfering effects been observed with the use of anticoagulants.

However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

**Revised of 3 Feb. 2009 (Vers. 1.0)****REFERENCES**

1. F.Bobbio-Pallavicini, C.Alpini, R.Caporali, S.Avalle, S.Bugatti, C.Montecuccio. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.  
Arthritis Res Ther 2004, 6:R264-R272 (DOI 10.1186/ar1173)
2. E.R.Vossenaar, N.Deprés, E.Lapointe, A.van der Heijden, M.Lora, T.Senshu, W.J. van Venfooj, H.A. Ménard. Rheumatoid arthritis specific anti Sa antibodies target citrullinated vimentin.  
Arthritis Research & Therapie Vol. 6 No. 2
3. M.Escalon, F.J.Lópees-Longo, C.M. González, I.Monteagudo, M.Rodriguez-Mahou, R.Grau, L.Carreno. Anti-Sa Sera from patients with Rheumatoid Arthritis contain at least 2 different subpopulations of Anti-Sa antibodies.  
The Journal of Rheumatology 2002; 29:10 2053-60
4. Ch.Vincent, L.Nogueira, M.Sebba, S.Chapuy-Regaud, M.Arnaud, O.Letourneur, D.Rolland, B.Rounie, A.Cantagrel, M.Jolivet, G.Serre. Detecion of antibodies to dertermined recombinant tat filaggrin by Enzyme-Linked Immunosorbent Assay.  
Arthritis & Rheumatism Vo. 46, No. 8, August 2002, pp. 2051-58
5. G.Steiner, J.Smolen. Antibodies in rheumatoid arthritis and their clinical significance.  
Arthritis Res 2002, 4 (suppl 2):S1-S5
6. R.Goldbach-Mansky, J.Lee, A.McCoy, J.Hoxworth, C.Yarboro, J.S.Smolen, G.Steiner, A.Rosen, C.Zhang, H.A.Ménard, Z.J.Zhou, T.Palosuo, W.J.Van Venrooij, R.L.Wilder, J.H.Klippel, H.R.Schumacher Jr., H.S.El-Gabalawy. Rheumatoid arthritis associated antibodies in patients with synovitis of recent onset.  
Arthritis Res 2000, 2:236-243



**DRG<sup>®</sup> ACPA (Anti-Citrullinated Protein Ab) (EIA-4848)**

USA:

Revised of 3 Feb. 2009 (Vers. 1.0)

**SYMBOLS USED WITH DRG ASSAYS**

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeitsdatum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità
Symbol	Portugues	Dansk	Svenska	Ελληνικά	
	Consulte as instruções de utilização	Se brugsanvisning	Se bruksanvisningen	Εγχειρίδιο χρήστη	
	Conformidade com as normas europeias	Europeisk overensstemmelse	Europeisk överensstämmelse	Ευρωπαϊκή Συμμόρφωση	
	Diagnóstico in vitro	In vitro diagnostik	Diagnostik in vitro	in vitro διαγνωστικό	
	Catálogo n.º	Katalognummer	Katalog nummer	Αριθμός καταλόγου	
	No do lote	Lot nummer	Batch-nummer	Αριθμός Παρτίδος	
		Indeholder tilstrækkeligt til "n" test	Innehåller tillräckligt till "n" tester	Περιεχόμενο επαρκές για «n» εξετάσεις	
	Temperatura de conservação	Opbevarings-temperatur	Förvaringstemperatur	Θερμοκρασία αποθήκευσης	
	Prazo de validade	Udløbsdato	Bäst före datum	Ημερομηνία λήξης	
	Fabricante	Producent	Tillverkare	Κατασκευαστής	
Volume/No.	Volume/Número	Volumen/antal	Volym/antal	Όγκος/αριθ..	